NewslettersHematopoiesis News Editas Medicine Receives FDA Orphan Drug Designation For EDIT-301 For The Treatment Of Sickle Cell Disease By Jamie Kang - May 1, 2023 0 Editas Medicine, Inc. announced that the US FDA granted Orphan Drug Designation to EDIT-301, an investigational, gene-editing medicine, for the treatment of sickle cell disease. [Editas Medicine, Inc.] Press Release